XNYS · Drug Manufacturers - General
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$62.80+1.06%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
68/100
Positive
Score components
TickerWhale View
Bristol-Myers Squibb Company scores 68 out of 100 overall, which we rate positive. Valuation is its strongest area and Risk its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
- Risk
- Sentiment Signal
Quality & growth
30%64Positive
- Revenue growth 3.1%
- EPS growth 83.1%
Valuation
25%96Strong
- P/E 13.9
- EV/Sales 3.3
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
#96 by market cap in our coverage · ~32,500 employees · Listed 1952-06-23 · www.bms.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#14 / 139sector rank by TickerWhale Score
TickerWhale Score 68 vs sector average 54.6 (+13.4)
Revenue growth (industry)Top 73%
Gross margin (industry)Top 73%
Return on equity (industry)Top 30%
P/E (industry)Cheaper than 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
64/100Positive vs universe
Ranks 64th of 100 covered names on our technical composite — the composite itself scores 65/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
4 buy · 0 sell · 4 neutral of 8 votes
TickerWhale rates BMY's technical setup middling — 64th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+4.3%
- vs 50-day+1.0%
Momentum
Mixed
- RSI (14)54 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength14· weak trend
- MACD (12,26,9)buy(histogram 0.203)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 0 sell · 4 neutral.
Result — 4 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)13.9
- P/S (TTM)2.6
- P/B5.8
- EV/EBITDA—
- EV/Sales3.3
- PEG—
Profitability & returns
- Gross margin70.2%
- Net margin18.9%
- ROE43.8%
- Debt/Equity1.93
Growth
- Revenue growth (YoY)3.1%
- EPS growth (YoY)83.1%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $128.6B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $48.2B | $48.3B | $45.0B |
| Gross profit | $34.3B | $34.3B | $34.3B |
| Operating income | $9.3B | -$8.4B | $8.4B |
| Net income | $7.1B | -$8.9B | $8.0B |
| EPS (diluted) | $3.46 | $-4.41 | $3.86 |
| Free cash flow | $12.8B | $13.9B | $12.7B |
| Cash | $10.2B | $10.3B | $11.5B |
| Total debt | $45.1B | $49.6B | $39.8B |
| Equity | $18.5B | $16.3B | $29.4B |
| Net debt | $34.9B | $39.3B | $28.3B |
| Debt / equity | 2.44 | 3.04 | 1.35 |
| Liabilities / assets | 0.79 | 0.82 | 0.69 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMYCurrentBristol-Myers Squibb Company | 68 | 65 | 13.9 | — | 5.8 | 3.3 | $62.80 | +1.06% | +3.1% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.